Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease

BACKGROUND: Immune checkpoint inhibitors (ICIs) are important new therapeutic options for the treatment of malignancy. Existing data on the relative safety of ICI treatment in patients with pre-existing autoimmune disease (AID) are limited. METHODS: In this retrospective study utilizing an oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Bender, David Andrew, Heilbroner, Samuel P, Wang, Tony J C, Shu, Catherine A, Hyde, Brigham, Spina, Catherine, Cheng, Simon K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733208/
https://www.ncbi.nlm.nih.gov/pubmed/33303578
http://dx.doi.org/10.1136/jitc-2020-001627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733208/
https://www.ncbi.nlm.nih.gov/pubmed/33303578
http://dx.doi.org/10.1136/jitc-2020-001627

Ejemplares similares